Proteogenomics leverages mass spectrometry (MS)-based proteomics data alongside genomics and transcriptomics data to identify neoantigens—unique peptide sequences arising from tumor-specific mutations
The ATLAS bioassay was developed to empirically identify neoantigens by expressing each unique patient-specific tumor mutation individually in E. coli, pulsing autologous dendritic cells in an ordered
